Systematic literature review of neutralizing antibody immune responses to non-vaccine targeted high-risk HPV types induced by the bivalent and the quadrivalent vaccines

Stanley, Margaret; Joura, Elmar A.; Yen, Glorian P.; Kothari, Smita; Luxembourg, Alain; Saah, Alfred J.; Walia, Anuj; Pérez, Gonzalo; Khoury, Hanane; Badgley, Danielle; Brown, Darron R.

doi:10.1016/j.vaccine.2021.01.060

Cited by 9 publications

(11 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…HPV vaccination has shown to reduce the HPV prevalence and HPV-related diseases, in countries with high vaccine coverage. [22][23][24] Evidence suggests that the bivalent and quadrivalent vaccines induce cross-protection against the not targeted types HPV31/33/45. 23 24 In Costa Rica, quadrivalent HPV vaccination was introduced in 2019 targeting girls aged 10 years, thus our estimates of prevalence/incidence of HPV infection did not benefit from the indirect protection by the vaccine-eligible cohorts of the vaccination programme.…”

Section: Discussionmentioning

confidence: 99%

“…The strengths of the present study include the large sample size and the use of well-validated HPV detection/genotyping methods 12. HPV vaccination has shown to reduce the HPV prevalence and HPV-related diseases, in countries with high vaccine coverage 22–24. Evidence suggests that the bivalent and quadrivalent vaccines induce cross-protection against the not targeted types HPV31/33/45 23 24.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Analysis of cervical HPV infections among unvaccinated young adult women to inform vaccine strategies in this age group: the Costa Rica HPV Vaccine Trial

et al. 2022

View full text Add to dashboard Cite

IntroductionHuman papillomavirus (HPV) vaccines protect against incident HPV infections, which cause cervical cancer.ObjectivesWe estimated the prevalence and incidence of HPV infections in young adult women to understand the impact of an HPV vaccination programme in this population.MethodsWe collected cervical specimens from 6322 unvaccinated women, aged 18–37 years, who participated in the Costa Rica Vaccine Trial and its long-term follow-up. Women were followed for (median) 4.8 years and had (median) 4.0 study visits. Cervical specimens were tested for the presence/absence of 25 HPV genotypes. For each age band, we estimated the percentage of women with 1+ prevalent or 1+ incident HPV infections using generalised estimating equations. We also estimated the prevalence and incidence of HPV as a function of time since first sexual intercourse (FSI).ResultsThe model estimated HPV incident infections peaked at 28.0% (95% CI 25.3% to 30.9%) at age 20 years then steadily declined to 11.8% (95% CI 7.6% to 17.8%) at age 37 years. Incident oncogenic HPV infections (HPV16/18/31/33/35/39/45/51/52/56/58/59) peaked and then declined from 20.3% (95% CI 17.9% to 22.9%) to 7.7% (95% CI 4.4% to 13.1%); HPV16/18 declined from 6.4% (95% CI 5.1% to 8.1%) to 1.1% (95% CI 0.33% to 3.6%) and HPV31/33/45/52/58 declined from 11.0% (95% CI 9.3% to 13.1%) to 4.5% (95% CI 2.2% to 8.9%) over the same ages. The percentage of women with 1+ incident HPV of any, oncogenic, non-oncogenic and vaccine-preventable (HPV16/18, HPV31/33/45, HPV31/33/45/52/58, and HPV6/11) types peaked <1 year after FSI and steadily declined with increasing time since FSI (p for trends <0.001). We observed similar patterns for model estimated HPV prevalences.ConclusionYoung adult women may benefit from HPV vaccination if newly acquired vaccine-preventable oncogenic infections lead to cervical precancer and cancer. HPV vaccination targeting this population may provide additional opportunities for primary prevention.Trial registration numberNCT00128661.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Analysis of cervical HPV infections among unvaccinated young adult women to inform vaccine strategies in this age group: the Costa Rica HPV Vaccine Trial

et al. 2022

View full text Add to dashboard Cite

show abstract

“…Not only the three common vaccines, but also the current status of vaccines ranging from 1v to 11v, which are designed differently from the expression system and the number of subtypes protected against HPV, are described. The three currently licensed prophylactic vaccines were all developed based on multiple types of mixed L1 VLPs that induce strong immunogenicity and produce high levels of antibody titers ( Stanley et al., 2021 ). However, from the clinical trials described above and the long-term follow-up, it appears that the antibody titer decreases significantly over time and varies greatly between individuals.…”

Section: Research Progress Of Hpv Prophylactic Vaccinesmentioning

confidence: 99%

“…For HPV prevention, periodic physical examination is important, while vaccination is the most economical and effective way. The currently available HPV vaccines are designed using a combination of multiple subtypes of L1-VLPs, and the L1 spontaneously formed VLPs are highly immunogenic and produce high titers of neutralizing antibodies to prevent HPV infection ( Stanley et al., 2021 ). Since 2006, the bivalent, quadrivalent and nonavalent vaccines have had relatively good preventive effects.…”

Section: Introductionmentioning

confidence: 99%

Prophylactic and Therapeutic HPV Vaccines: Current Scenario and Perspectives

Ma²,

Zhang³

et al. 2022

Front. Cell. Infect. Microbiol.

View full text Add to dashboard Cite

Persistent human papillomavirus (HPV) infection is recognized as the main cause of cervical cancer and other malignant cancers. Although early detection and treatment can be achieved by effective HPV screening methods and surgical procedures, the disease load has not been adequately mitigated yet, especially in the underdeveloped areas. Vaccine, being regarded as a more effective solution, is expected to prevent virus infection and the consequent diseases in the phases of both prevention and treatment. Currently, there are three licensed prophylactic vaccines for L1-VLPs, namely bivalent, quadrivalent and nonavalent vaccine. About 90% of HPV infections have been effectively prevented with the implementation of vaccines worldwide. However, no significant therapeutic effect has been observed on the already existed infections and lesions. Therapeutic vaccine designed for oncoprotein E6/E7 activates cellular immunity rather than focuses on neutralizing antibodies, which is considered as an ideal immune method to eliminate infection. In this review, we elaborate on the classification, mechanism, and clinical effects of HPV vaccines for disease prevention and treatment, in order to make improvements to the current situation of HPV vaccines by provoking new ideas.

show abstract

“…Detection of serum antibodies to HPV capsids is a valid marker for immune response prior to vaccination [ 31 ]. Since antibodies developed upon receiving the HPV vaccine are highly protective for high-grade cervical disease development, we reasoned that detection of an incident cervical HPV16 or HPV31 infection in HPV vaccine recipients would be associated with lower antibody titers compared to women similarly immunized but without detectable new infections.…”

Section: Introductionmentioning

confidence: 99%

Anti-HPV16 Antibody Titers Prior to an Incident Cervical HPV16/31 Infection

Gradíssimo

Shankar

Wiek

et al. 2021

Viruses

View full text Add to dashboard Cite

The goal of this study was to investigate the serological titers of circulating antibodies against human papillomavirus (HPV) type 16 (anti-HPV16) prior to the detection of an incident HPV16 or HPV31 infection amongst vaccinated participants. Patients were selected from a prospective post-HPV vaccine longitudinal cohort at Mount Sinai Adolescent Health Center in Manhattan, NY. We performed a nested case–control study of 43 cases with incident detection of cervical HPV16 (n = 26) or HPV31 (n = 17) DNA who had completed the full set of immunizations of the quadrivalent HPV vaccine (4vHPV). Two control individuals whom had received three doses of the vaccine (HPV16/31-negative) were selected per case, matched on age at the first dose of vaccination and follow-up time in the study: a random control, and a high-risk control that was in the upper quartile of a sexual risk behavior score. We conducted an enzyme-linked immunosorbent assay (ELISA) for the detection of immunoglobulin G (IgG) antibodies specific to anti-HPV16 virus-like particles (VLPs). The results suggest that the average log antibody titers were higher among high-risk controls than the HPV16/31 incident cases and the randomly selected controls. We show a prospective association between anti-HPV16 VLP titers and the acquisition of an HPV16/31 incident infection post-receiving three doses of 4vHPV vaccine.

show abstract

Systematic literature review of neutralizing antibody immune responses to non-vaccine targeted high-risk HPV types induced by the bivalent and the quadrivalent vaccines

Cited by 9 publications

References 38 publications

Analysis of cervical HPV infections among unvaccinated young adult women to inform vaccine strategies in this age group: the Costa Rica HPV Vaccine Trial

Analysis of cervical HPV infections among unvaccinated young adult women to inform vaccine strategies in this age group: the Costa Rica HPV Vaccine Trial

Prophylactic and Therapeutic HPV Vaccines: Current Scenario and Perspectives

Anti-HPV16 Antibody Titers Prior to an Incident Cervical HPV16/31 Infection

Contact Info

Product

Resources

About